Skip to main content

NCT00207740 - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


CSR Summary

Not Yet Available


Data Specification

Available upon data request approval


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Golimumab
Product Name
SIMPONIĀ®
Therapeutic Area
Respiratory Tract (Lung and Bronchial) Diseases
Enrollment
309
% Female
56.0%
% White
88.0%
Product Class
Antirheumatic Agents - Biologic Response Modifiers
Sponsor Protocol Number
C0524T03
Data Partner
Johnson & Johnson
Condition Studied
Asthma
Mean/Median Age (Years)
50.1

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.